Physician

Adam Garretson Rock, M.D.

According to 2025 Medicare claims, Adam Rock, M.D. (NPI: 1477907715) practices medical oncology in the Los Angeles-Long Beach-Glendale, CA market, with the plurality of this provider's patient population coming from Los Angeles, CA. This provider's primary affiliated billing organization is CITY OF HOPE MEDICAL FOUNDATION (NPI: 1871886366; TIN: 274803222) and primary practice location at 91010-3012.

Rock's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 251 traditional Medicare patients, billed 1,083 HCPCS/CPT codes, and received $79,801 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 722 prescription claims across 127 beneficiaries totaling $4,471,592 in drug costs, led by Tagrisso (Osimertinib Mesylate). DME data shows 12 claims. Open Payments data shows 44 records totaling $731,881. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $5,153 to $4,471,592. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	133	268	$21,970
2023	225	766	$67,203
2024	251	1,083	$79,801

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	N/R	30	$5,153
2017	36	118	$20,190
2018	41	233	$25,687
2019	58	215	$173,112
2020	32	170	$618,942
2021	80	347	$1,980,018
2022	138	476	$2,455,985
2023	121	745	$6,412,597
2024	127	722	$4,471,592

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	12	$858

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	55	55	$151
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	127	243	$120
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	182	361	$85
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	30	45	$61
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	155	343	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tagrisso	Osimertinib Mesylate	143	4,350	$2,439,768
Alecensa	Alectinib Hcl	19	630	$355,057
Lorbrena	Lorlatinib	16	480	$272,512
Xtandi	Enzalutamide	18	540	$240,517
Inlyta	Axitinib	12	360	$167,649

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	12	$858

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	5	$242	Novocure Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	39	$731,639	City Of Hope National Medical Ctr
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adam Garretson Rock, M.D.?

Tedicare shows public-source Medicare data for Adam Garretson Rock, M.D. (NPI 1477907715), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adam Garretson Rock, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Adam Garretson Rock, M.D.?

Adam Garretson Rock, M.D. is linked to CITY OF HOPE MEDICAL FOUNDATION (billing NPI 1871886366) in the available physician profile data.

Does Adam Garretson Rock, M.D. have Open Payments data?

Adam Garretson Rock, M.D. has 44 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.